Crow, J. M. HPV: The global burden Nature 2012, 488, S2 10.1038/488S2a
Forman, D.; de Martel, C.; Lacey, C. J.; Soerjomataram, I.; Lortet-Tieulent, J.; Bruni, L.; Vignat, J.; Ferlay, J.; Bray, F.; Plummer, M.; Franceschi, S. Global burden of human papillomavirus and related diseases Vaccine 2012, 30 ( Suppl 5 ) F12-23 10.1016/j.vaccine.2012.07.055
Bzhalava, D.; Guan, P.; Franceschi, S.; Dillner, J.; Clifford, G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types Virology 2013, 445 ( 1-2 ) 224-31 10.1016/j.virol.2013.07.015
Bosch, F. X.; Broker, T. R.; Forman, D.; Moscicki, A.-B.; Gillison, M. L.; Doorbar, J.; Stern, P. L.; Stanley, M.; Arbyn, M.; Poljak, M.; Cuzick, J.; Castle, P. E.; Schiller, J. T.; Markowitz, L. E.; Fisher, W. A.; Canfell, K.; Denny, L. A.; Franco, E. L.; Steben, M.; Kane, M. A.; Schiffman, M.; Meijer, C. J. L. M.; Sankaranarayanan, R.; Castellsagué, X.; Kim, J. J.; Brotons, M.; Alemany, L.; Albero, G.; Diaz, M.; Sanjosé, S. d. Comprehensive Control of Human Papillomavirus Infections and Related Diseases Vaccine 2013, 31 ( S8 ) I1-I31 10.1016/j.vaccine.2013.07.026
Doorbar, J.; Quint, W.; Banks, L.; Bravo, I. G.; Stoler, M.; Broker, T. R.; Stanley, M. A. The biology and life-cycle of human papillomaviruses Vaccine 2012, 30 ( S5 ) F55-70 10.1016/j.vaccine.2012.06.083
Govan, V. A. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes Ann. N. Y. Acad. Sci. 2005, 1056, 328-43 10.1196/annals.1352.016
Ghittoni, R.; Accardi, R.; Hasan, U.; Gheit, T.; Sylla, B.; Tommasino, M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses Virus Genes 2010, 40 ( 1 ) 1-13 10.1007/s11262-009-0412-8
Zhang, T.; Zhao, C.; Luo, L.; Zhao, H.; Cheng, J.; Xu, F. The expression of Mcl-1 in human cervical cancer and its clinical significance Med. Oncol. 2012, 29 ( 3 ) 1985-91 10.1007/s12032-011-0005-y
Akgul, C. Mcl-1 is a potential therapeutic target in multiple types of cancer Cell. Mol. Life Sci. 2009, 66 ( 8 ) 1326-36 10.1007/s00018-008-8637-6
Vela, L.; Marzo, I. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside Curr. Opin. Pharmacol. 2015, 23, 74-81 10.1016/j.coph.2015.05.014
Jiang, M.; Milner, J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference Oncogene 2002, 21, 6041-6048 10.1038/sj.onc.1205878
Yoshinouchi, M.; Yamada, T.; Kizaki, M.; Fen, J.; Koseki, T.; Ikeda, Y.; Nishihara, T.; Yamato, K. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA Mol. Ther. 2003, 8 ( 5 ) 762-768 10.1016/j.ymthe.2003.08.004
Wu, S. Y.; Singhania, A.; Burgess, M.; Putral, L. N.; Kirkpatrick, C.; Davies, N. M.; McMillan, N. A. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models Gene Ther. 2011, 18 ( 1 ) 14-22 10.1038/gt.2010.113
Li, S. D.; Chono, S.; Huang, L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA Mol. Ther. 2008, 16 ( 5 ) 942-6 10.1038/mt.2008.51
Huang, L.; Jin, J.; Deighan, P.; Kiner, E.; McReynolds, L.; Lieberman, J. Efficient and specific gene knockdown by small interfering RNAs produced in bacteria Nat. Biotechnol. 2013, 31 ( 4 ) 350-6 10.1038/nbt.2537
Wittrup, A.; Lieberman, J. Knocking down disease: a progress report on siRNA therapeutics Nat. Rev. Genet. 2015, 16 ( 9 ) 543-52 10.1038/nrg3978
Yang, M.; Yu, T.; Wang, Y. Y.; Lai, S. K.; Zeng, Q.; Miao, B.; Tang, B. C.; Simons, B. W.; Ensign, L. M.; Liu, G.; Chan, K. W.; Juang, C. Y.; Mert, O.; Wood, J.; Fu, J.; McMahon, M. T.; Wu, T. C.; Hung, C. F.; Hanes, J. Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth Adv. Healthcare Mater. 2014, 3 ( 7 ) 1044-52 10.1002/adhm.201300519
Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. RNA interference in the clinic: challenges and future directions Nat. Rev. Cancer 2011, 11 ( 1 ) 59-67 10.1038/nrc2966
Thompson, J. D. Clinical development of synthetic siRNA therapeutics Drug Discovery Today: Ther. Strategies 2013, 10 ( 3 ) e133-e138 10.1016/j.ddstr.2013.03.002
Yang, S.; Chen, Y.; Ahmadie, R.; Ho, E. A. Advancements in the Field of Intravaginal siRNA Delivery J. Controlled Release 2013, 167 ( 1 ) 29-39 10.1016/j.jconrel.2012.12.023
Sosnik, A.; das Neves, J.; Sarmento, B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review Prog. Polym. Sci. 2014, 39 ( 12 ) 2030-2075 10.1016/j.progpolymsci.2014.07.010
Steinbach, J. M.; Weller, C. E.; Booth, C. J.; Saltzman, W. M. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection J. Controlled Release 2012, 162 ( 1 ) 102-10 10.1016/j.jconrel.2012.06.008
Wu, S. Y.; Chang, H.-I.; Burgess, M.; McMillan, N. A. J. Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system J. Controlled Release 2011, 155 ( 3 ) 418-426 10.1016/j.jconrel.2011.02.002
Woodrow, K. A.; Cu, Y.; Booth, C. J.; Saucier-Sawyer, J. K.; Wood, M. J.; Saltzman, W. M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA Nat. Mater. 2009, 8 ( 6 ) 526-33 10.1038/nmat2444
Lai, S. K.; Wang, Y. Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues Adv. Drug Delivery Rev. 2009, 61 ( 2 ) 158-71 10.1016/j.addr.2008.11.002
Dunnhaupt, S.; Kammona, O.; Waldner, C.; Kiparissides, C.; Bernkop-Schnurch, A. Nano-carrier systems: Strategies to overcome the mucus gel barrier Eur. J. Pharm. Biopharm. 2015, 96, 447 10.1016/j.ejpb.2015.01.022
Wang, Y. Y.; Lai, S. K.; Suk, J. S.; Pace, A.; Cone, R.; Hanes, J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that slip through the human mucus barrier Angew. Chem., Int. Ed. 2008, 47 ( 50 ) 9726-9 10.1002/anie.200803526
Lechanteur, A.; Furst, T.; Evrard, B.; Delvenne, P.; Hubert, P.; Piel, G. Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions Int. J. Pharm. 2015, 483, 268-277 10.1016/j.ijpharm.2015.02.041
Lechanteur, A.; Furst, T.; Evrard, B.; Delvenne, P.; Hubert, P.; Piel, G. PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness Eur. J. Pharm. Sci. 2016, 93, 493-503 10.1016/j.ejps.2016.08.058
Rabanel, J. M.; Hildgen, P.; Banquy, X. Assessment of PEG on polymeric particles surface, a key step in drug carrier translation J. Controlled Release 2014, 185, 71-87 10.1016/j.jconrel.2014.04.017
Xia, Y.; Tian, J.; Chen, X. Effect of Surface Properties on Liposomal siRNA Delivery Biomaterials 2016, 79, 56-68 10.1016/j.biomaterials.2015.11.056
Chang, J. T.; Kuo, T. F.; Chen, Y. J.; Chiu, C. C.; Lu, Y. C.; Li, H. F.; Shen, C. R.; Cheng, A. J. Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers Cancer Gene Ther. 2010, 17 ( 12 ) 827-36 10.1038/cgt.2010.38
Rajalingam, K.; Sharma, M.; Lohmann, C.; Oswald, M.; Thieck, O.; Froelich, C. J.; Rudel, T. Mcl-1 is a key regulator of apoptosis resistance in Chlamydia trachomatis-infected cells PLoS One 2008, 3 ( 9 ) e3102 10.1371/journal.pone.0003102
Furst, T.; Dakwar, G. R.; Zagato, E.; Lechanteur, A.; Remaut, K.; Evrard, B.; Braeckmans, K.; Piel, G. Freeze-dried mucoadhesive polymeric system containing pegylated lipoplexes: Towards a vaginal sustained released system for siRNA J. Controlled Release 2016, 236, 68-78 10.1016/j.jconrel.2016.06.028
Furst, T.; Piette, M.; Lechanteur, A.; Evrard, B.; Piel, G. Mucoadhesive cellulosic derivative sponges as drug delivery system for vaginal application Eur. J. Pharm. Biopharm. 2015, 95, 128-135 10.1016/j.ejpb.2015.01.019
Belletti, D.; Tosi, G.; Forni, F.; Lagreca, I.; Barozzi, P.; Pederzoli, F.; Vandelli, M. A.; Riva, G.; Luppi, M.; Ruozi, B. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity Eur. J. Pharm. Biopharm. 2016, 99, 7-17 10.1016/j.ejpb.2015.11.007
Qu, M.-H.; Zeng, R.-F.; Fang, S.; Dai, Q.-S.; Li, H.-P.; Long, J.-T. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer Int. J. Pharm. 2014, 474 ( 1-2 ) 112-122 10.1016/j.ijpharm.2014.08.019
Reschner, A.; Bontems, S.; Le Gac, S.; Lambermont, J.; Marcelis, L.; Defrancq, E.; Hubert, P.; Moucheron, C.; Kirsch-De Mesmaeker, A.; Raes, M.; Piette, J.; Delvenne, P. Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53 Gene Ther. 2013, 20 ( 4 ) 435-43 10.1038/gt.2012.54
Lea, J. S.; Sunaga, N.; Sato, M.; Kalahasti, G.; Miller, D. S.; Minna, J. D.; Muller, C. Y. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells Reprod. Sci. 2007, 14 ( 1 ) 20-8 10.1177/1933719106298189
Hill, A. B.; Chen, M.; Chen, C.-K.; Pfeifer, B. A.; Jones, C. H. Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors Trends Biotechnol. 2016, 34 ( 2 ) 91-105 10.1016/j.tibtech.2015.11.004
Masotti, A.; Mossa, G.; Cametti, C.; Ortaggi, G.; Bianco, A.; Grosso, N. D.; Malizia, D.; Esposito, C. Comparison of different commercially available cationic liposome-DNA lipoplexes: Parameters influencing toxicity and transfection efficiency Colloids Surf., B 2009, 68 ( 2 ) 136-44 10.1016/j.colsurfb.2008.09.017
Douglas, K. L.; Piccirillo, C. A.; Tabrizian, M. Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors Eur. J. Pharm. Biopharm. 2008, 68 ( 3 ) 676-87 10.1016/j.ejpb.2007.09.002
Lee, S. J.; Cho, Y. S.; Cho, M. C.; Shim, J. H.; Lee, K. A.; Ko, K. K.; Choe, Y. K.; Park, S. N.; Hoshino, T.; Kim, S.; Dinarello, C. A.; Yoon, D. Y. Both E6 and E7 Oncoproteins of Human Papillomavirus 16 Inhibit IL-18-Induced IFN-Production in Human Peripheral Blood Mononuclear and NK Cells J. Immunol. 2001, 167 ( 1 ) 497-504 10.4049/jimmunol.167.1.497
Xu, Q.; Ensign, L.; Boylan, N.; Schön, A.; Gong, X.; Yang, J.-C.; Lamb, N. W.; Cai, S.; Yu, T.; Freire, E.; Hanes, J. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticles Transport in Mucus ex Vivo and Distribution in Vivo ACS Nano 2015, 9 ( 9 ) 9217-9227 10.1021/acsnano.5b03876
Ensign, L. M.; Tang, B. C.; Wang, Y. Y.; Tse, T. A.; Hoen, T.; Cone, R.; Hanes, J. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus Sci. Transl. Med. 2012, 4 ( 138 ) 138ra79 10.1126/scitranslmed.3003453
das Neves, J.; Araujo, F.; Andrade, F.; Michiels, J.; Arien, K. K.; Vanham, G.; Amiji, M.; Bahia, M. F.; Sarmento, B. In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine Mol. Pharmaceutics 2013, 10 ( 7 ) 2793-807 10.1021/mp4002365
van Eyk, A. D.; van der Bijl, P. Porcine vaginal mucosa as an in vitro permeability model for human vaginal mucosa Int. J. Pharm. 2005, 305 ( 1-2 ) 105-11 10.1016/j.ijpharm.2005.09.002
Cu, Y.; Booth, C. J.; Saltzman, W. M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery J. Controlled Release 2011, 156 ( 2 ) 258-64 10.1016/j.jconrel.2011.06.036
Palliser, D.; Chowdhury, D.; Wang, Q. Y.; Lee, S. J.; Bronson, R. T.; Knipe, D. M.; Lieberman, J. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection Nature 2006, 439 ( 7072 ) 89-94 10.1038/nature04263
